Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H33NO6 |
| Molecular Weight | 455.5433 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC=C2\C=C\C(=O)OC(C)(C)C)C(=O)OCC
InChI
InChIKey=GKQPCPXONLDCMU-CCEZHUSRSA-N
InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/14524737
Sources: http://www.ncbi.nlm.nih.gov/pubmed/14524737
Lacidipine (tradenames Lacipil (GSK) or Motens (Boehringer Ingelheim) is a once-daily, orally-administered, lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity, resulting in a lack of reflex tachycardia. It has a long duration of action and a high degree of vascular selectivity. In addition to calcium channel-modulated vasodilation, lacidipine displays antioxidant activity greater than that of other dihydropyridine calcium antagonists. During long-term treatment for 4 or 5 years in patients with isolated systolic hypertension or essential hypertension, the incidence of cardiovascular events and mortality with lacidipine was similar to that with chlorthalidone or atenolol
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2219960
Curator's Comment: Only traces of radioactivity were detected in the CNS and in rat foetuses
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2363032 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1725443 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats. | 2009-08 |
|
| Lercanidipine in the treatment of hypertension. | 2007-03 |
|
| Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. | 2002-12 |
|
| Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. | 2002-11 |
|
| Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding. | 1999-12 |
|
| [Preclinical study of the action of a calcium channel blocker during salt load]. | 1997-02 |
|
| Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study. | 1996-08 |
|
| Lacidipine: a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies. | 1990-04 |
|
| Haemodynamic parameters in hypertensive patients: changes induced by lacidipine and nifedipine. | 1989-12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.tevauk.com/mediafile/id/9070.pdf
2 mg tablet once-daily every morning
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1691391
Lacidipine (10(-8) -10(-6) M) dose-dependently decreased contractility of driven sheep Purkinje fibers. For concentrations less than or equal to 10(-7) M, this effect was associated with a selective decrease of the plateau height. Higher concentrations (3 X 10(-7) and 10(-6) M), however, affected action potential amplitude, overshoot, and maximum rate of depolarization. In the same range of concentrations, lacidipine did not affect normal automaticity of guinea-pig sinus node and sheep Purkinje fibers. Lacidipine (10(-6) M) consistently blocked barium-induced abnormal automaticity in Purkinje fibers and reduced the amplitude and Vmax of the slow action potentials induced by histamine (10(-5) M) in guinea pig papillary muscle depolarized by potassium (22 mM). The effect of lacidipine on the slow inward current (Isi) was studied in shortened Purkinje fibers under voltage-clamp conditions.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
C08CA09
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
||
|
WHO-VATC |
QC08CA09
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL460291
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
28382
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB08383MIG
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
103890-78-4
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
260080034N
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
DTXSID1046429
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
DB09236
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
m6649
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | Merck Index | ||
|
C060285
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
LACIDIPINE
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
AA-42
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
1532
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
6093
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
C80881
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
100000087153
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY | |||
|
5311217
Created by
admin on Wed Apr 02 06:51:47 GMT 2025 , Edited by admin on Wed Apr 02 06:51:47 GMT 2025
|
PRIMARY |
ACTIVE MOIETY